HK1115131A1 - Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4- [(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor - Google Patents

Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4- [(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor

Info

Publication number
HK1115131A1
HK1115131A1 HK08110550.3A HK08110550A HK1115131A1 HK 1115131 A1 HK1115131 A1 HK 1115131A1 HK 08110550 A HK08110550 A HK 08110550A HK 1115131 A1 HK1115131 A1 HK 1115131A1
Authority
HK
Hong Kong
Prior art keywords
iminomethyl
polymorphs
benzamide
pyridinyl
dimethylamino
Prior art date
Application number
HK08110550.3A
Other languages
English (en)
Inventor
Craig Grant
James P Kanter
Graeme Langlands
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1115131A1 publication Critical patent/HK1115131A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK08110550.3A 2005-11-08 2008-09-23 Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4- [(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor HK1115131A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73522405P 2005-11-08 2005-11-08
PCT/US2006/043635 WO2007056517A2 (en) 2005-11-08 2006-11-07 Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor

Publications (1)

Publication Number Publication Date
HK1115131A1 true HK1115131A1 (en) 2008-11-21

Family

ID=38023988

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110550.3A HK1115131A1 (en) 2005-11-08 2008-09-23 Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4- [(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor

Country Status (21)

Country Link
US (7) US7598276B2 (xx)
EP (2) EP2431358A1 (xx)
JP (2) JP5227178B2 (xx)
KR (1) KR101358574B1 (xx)
CN (2) CN102336702B (xx)
AR (2) AR056787A1 (xx)
AT (1) ATE549317T1 (xx)
AU (1) AU2006311544B2 (xx)
BR (1) BRPI0618362A2 (xx)
CA (1) CA2627086C (xx)
DK (1) DK1948608T3 (xx)
ES (1) ES2384116T3 (xx)
HK (1) HK1115131A1 (xx)
IL (2) IL190524A (xx)
NZ (2) NZ592533A (xx)
PE (2) PE20070717A1 (xx)
PT (1) PT1948608E (xx)
RU (1) RU2440986C2 (xx)
TW (1) TWI443088B (xx)
WO (1) WO2007056517A2 (xx)
ZA (1) ZA200803820B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
CA2651303A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
WO2008073670A2 (en) * 2006-12-08 2008-06-19 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
US20080293704A1 (en) * 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
AU2008239659B2 (en) * 2007-04-13 2013-09-05 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
EP2586439A1 (en) * 2007-05-02 2013-05-01 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet ADP receptor inhibitor
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
EP3604510A1 (en) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CA2784921A1 (en) * 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
ES2610145T3 (es) 2009-12-17 2017-04-26 Millennium Pharmaceuticals, Inc. Procedimientos de síntesis de inhibidores del factor Xa
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
AR082804A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
US20150224091A1 (en) 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US9200268B2 (en) * 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
CN107073082B (zh) 2014-08-20 2021-04-30 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
EP3419650B1 (en) 2016-02-24 2021-06-02 Alexion Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
EP3463352A4 (en) * 2016-06-02 2019-10-30 Dr. Reddy S Laboratories Limited POLYMORPH OF BETRIXABAN AND ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
DK3472314T3 (da) 2016-06-17 2021-07-26 Alexion Pharma Inc Fremstilling af faktor-xa-derivater
WO2018042320A1 (en) * 2016-08-30 2018-03-08 Dr. Reddy’S Laboratories Limited Salts of betrixaban and processes for preparation thereof
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN108017576B (zh) * 2016-11-01 2022-06-21 石药集团中奇制药技术（石家庄）有限公司 一种贝曲西班及其盐酸盐的制备方法，以及它们的晶型
CN108586325A (zh) * 2017-03-16 2018-09-28 上海度德医药科技有限公司 一种Betrixaban中间体的制备方法
WO2018229796A2 (en) 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
WO2022211680A1 (ru) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Способ получения антикоагулянта n-(5-хлорпиридин-2-ил)-2-({4-[этан-имидоил(метил)амино]бензоил}амино)-5-метилбензамид гидрохлорида
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013693A1 (en) 1992-12-15 1994-06-23 Corvas International, Inc. NOVEL INHIBITORS OF FACTOR Xa
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
EP0798295B1 (en) 1994-12-02 2003-02-26 Yamanouchi Pharmaceutical Co. Ltd. Novel amidinonaphthyl derivative or salt thereof
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
PL334250A1 (en) 1996-12-23 2000-02-14 Du Pont Pharm Co Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor
EP1020434A4 (en) 1997-08-27 2000-11-15 Kissei Pharmaceutical 3-AMIDINOANILINE DERIVATIVES, INHIBITORS OF THE ACTIVATED BLOOD COINTENANCE FACTOR X AND INTERMEDIATE PRODUCTS FOR PRODUCING BOTH
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
KR100760434B1 (ko) * 1999-09-17 2007-10-04 밀레니엄 파머슈티컬스 인코퍼레이티드 벤즈아미드 및 관련된 Ｘａ 인자의 억제제
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DK1259485T3 (da) * 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor

Also Published As

Publication number Publication date
US9555023B2 (en) 2017-01-31
JP2009514976A (ja) 2009-04-09
US20140288028A1 (en) 2014-09-25
US20130064806A1 (en) 2013-03-14
TWI443088B (zh) 2014-07-01
IL190524A0 (en) 2008-12-29
US20190046510A1 (en) 2019-02-14
JP5227178B2 (ja) 2013-07-03
IL213487A0 (en) 2011-07-31
AU2006311544A1 (en) 2007-05-18
CA2627086C (en) 2016-04-05
CN102336702A (zh) 2012-02-01
RU2008123055A (ru) 2009-12-20
PT1948608E (pt) 2012-05-24
US20170326119A1 (en) 2017-11-16
EP1948608A2 (en) 2008-07-30
PE20110070A1 (es) 2011-03-04
NZ592533A (en) 2012-08-31
EP1948608B1 (en) 2012-03-14
US20160101089A1 (en) 2016-04-14
KR101358574B1 (ko) 2014-02-04
AU2006311544B2 (en) 2012-03-08
WO2007056517A3 (en) 2008-04-17
US8557852B2 (en) 2013-10-15
TW200736221A (en) 2007-10-01
BRPI0618362A2 (pt) 2011-08-30
US9061019B2 (en) 2015-06-23
CN101304971A (zh) 2008-11-12
IL190524A (en) 2013-02-28
JP2012246323A (ja) 2012-12-13
AR106960A2 (es) 2018-03-07
JP5662980B2 (ja) 2015-02-04
CN101304971B (zh) 2011-09-07
EP2431358A1 (en) 2012-03-21
ATE549317T1 (de) 2012-03-15
DK1948608T3 (da) 2012-07-02
RU2440986C2 (ru) 2012-01-27
ZA200803820B (en) 2009-03-25
US7598276B2 (en) 2009-10-06
WO2007056517A2 (en) 2007-05-18
AR056787A1 (es) 2007-10-24
CN102336702B (zh) 2015-02-11
ES2384116T3 (es) 2012-06-29
US20070112039A1 (en) 2007-05-17
NZ567992A (en) 2011-05-27
PE20070717A1 (es) 2007-08-17
US20100063113A1 (en) 2010-03-11
CA2627086A1 (en) 2007-05-18
KR20080065662A (ko) 2008-07-14

Similar Documents

Publication Publication Date Title
HK1115131A1 (en) Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4- [(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor
FIC20210010I1 (fi) Fedratinibi tai sen farmaseuttisesti hyväksyttävä suola tai sen farmaseuttisesti hyväksyttävä hydraatti, erityisesti fedratinibidihydrokloridimonohydraatti
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
CL2007002930A1 (es) Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
DK1589005T3 (da) Fremgangsmåde til syntese af ivabradin og additionssalte heraf med en farmaceutisk acceptabel syre
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
SI2024341T1 (sl) Novi postopek za statine in njihove farmacevtsko sprejemljive soli
ZA200801351B (en) Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors
IL186308A (en) A pharmaceutical composition containing metformin hydrochloride and pioglitazone hydrochloride
HK1105588A1 (en) Diketopiperazine salts for drug delivery
HK1113543A1 (en) Aliphatic amine polymer salts for tableting
IL225167A (en) Annotations (para-methoxy) phenyl-sulfonamide, n- (isobutyl), n - [(r2) - hydroxy- (r3) - benzyl-profile]
DK1614687T3 (da) Fremgangsmåde til fremstilling af 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onderivater og deres anvendelse ved syntese af ivabradin og farmaceutisk acceptable salte deraf
WO2006090268A3 (en) Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin
DK1848419T3 (da) Injektionspræparater med diclofenac og farmaceutisk acceptable salte deraf
DK1589014T3 (da) Fremgangsmåde til syntese af derivater af 1,3-dihydro-2H-3-benzazepin-2-on og anvendelse heraf ved syntese af ivabradin og additionssalte heraf med en farmaceutisk acceptabel syre
EP1900735A4 (en) PYRIDAZINYLAMINE DERIVATIVES, USE OF DERIVATIVES IN THE PREPARATION OF PICORNAVIRUS INHIBITORS
EP1795526A4 (en) N-SUBSTITUTED N- (4-PIPERIDINYL) AMIDE DERIVATIVE
EP1878719A4 (en) HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL
EP1802575A4 (en) POLYMORPH OF N, N-DIETHYL-4- (3-FLUORPHENYLPIPERIDIN-4-YLIDENETHYL) -BENZAMIDE HYDROCHLORIDE SALT
HK1103075A1 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
ZA200708494B (en) 4-(pyrid-2-yl) amino substituted pyrimidime as protein kinase inhibitors
FR2893841B1 (fr) Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211107